Organon Q1 2024 revenue up 5% to $1.62B; adjusted EPS $1.22, up 13% YoY; 2024 guidance reaffirmed

Organon & Co.

2024-Q1 EPS reported $0.78 revenue$1,622,000,000

Q1 revenue $1,622M (+5% as-reported, +7% constant currency); net income $201M (+14% YoY).
GAAP diluted EPS $0.78; non-GAAP adjusted diluted EPS $1.22 (+13% YoY); includes $0.05 IPR&D/milestone charge.
Women's Health revenue +11% on Nexplanon (+34% ex-FX); Biosimilars +46% led by Hadlima ($30M vs $5M).
Adjusted EBITDA $538M, margin 33.2%; full-year 2024 financial guidance ranges affirmed.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Organon & Co. reported the first quarter ended March 31, 2024 results: revenue $1,622 million, net income $201 million, EPS $0.78. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $1,622 million
Net income: $201 million
EPS: $0.78
Guidance: reaffirmed
Result: reported results

Exact text from the filing

First quarter 2024 revenue of $1,622 million, up 5% on an as-reported basis and 7% at constant currency • First quarter 2024 diluted earnings per share of $0.78 and non-GAAP Adjusted diluted earnings per share of $1.22; both reported and non-GAAP Adjusted diluted earnings per share include $15 million expense, or $(0.05) per share, for acquired in-process research and development (IPR&D) and milestones • First quarter 2024 net income of $201 million and Adjusted EBITDA (non-GAAP) of $538 million • Full year 2024 financial guidance ranges affirmed

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Organon & Co. filing history →

Source: SEC EDGAR

accession 0001104659-24-056017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.